Cannabis 2.0 boosts legal cannabis sales in Canada

大麻2.0在加拿大促进合法大麻销售

2020-07-15 00:03:04 Prohibition Partners

本文共417个字,阅读需2分钟

July 10th, 2020 Arnau Valdovinos Agustí  – Consultant   Health Canada has resumed the publication of monthly data on the Canadian market that had been stopped due to the COVID19 pandemic. Due to changes in the reporting following the implementation of the Cannabis Tracking System Order last October, now the data is expressed in terms of packaged units instead of volume/weight. Medical flower sales experienced a 21% CAGR in the period between October and April. Medical extracts have grown at a 33% CAGR over the same period and represent an ever-larger share of the Canadian medical scheme. However, edibles and topicals remain a marginal category in the market. It is important to note that the average price per packaged unit (not reported by Health Canada) is higher in the case of extracts than in flower, and in terms of market value, extract sales generate more revenue than flower sales. Regarding adult-use sales, most growth in the category has been brought by the roll-out of Cannabis 2.0 products which started last December, especially thanks to edibles (which in this context also includes beverages), a category that is bringing a lot of attention lately. While flower-sales are stalled in the recreational market at a 0% CAGR, extracts are showing strong growth having more than doubled over the 6-month period.    
2020年7月10日 Arnau Valdovinos Agust í顾问 加拿大卫生部已恢复公布由于 COVID19大流行而停止的加拿大市场的月度数据。 由于在去年10月执行《 Cannabis 跟踪系统命令》后,报告发生了变化,现在数据以包装单位表示,而不是以体积/重量表示。 10月至4月间,医用花卉销售经历了21%的复合年增长率。同期,医用提取物的复合年增长率为33%,在加拿大医疗计划中所占份额越来越大。然而,在市场上,食用和外用仍然是一个边缘类别。值得注意的是,在提取物的情况下,每个包装单位的平均价格(加拿大卫生部未报告)高于花,从市场价值来看,提取物销售产生的收入大于花销售。 关于成人使用的销售,该类别的大部分增长是由于去年12月开始推出的大麻2.0产品,特别是由于食用(在这方面也包括饮料),这一类别最近引起了很多关注。尽管娱乐市场的花卉销售以0%的复合年增长率停滞不前,但提取物的强劲增长在6个月期间翻了一番多。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文